Just-Evotec Biologics has announced that it will be expanding a partnership struck with Sandoz in 2023 to develop and manufacture biosimilars, potentially adding further biosimilars to the pair’s development pipeline and offering “further guarantees for Sandoz’s long-term commercial supply security.”
Last year, Sandoz and Just-Evotec announced a “multi-year” deal to develop and manufacture multiple biosimilars, in particular making use of a “proprietary AI-driven technology platform that delivers fully
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?